polyclonal rabbit antibodies against cytochrome c  (Agrisera)

Journal: International Journal of Molecular Sciences

Article Title: Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway

doi: 10.3390/ijms23115967

Figure Lengend Snippet: Representative photomicrographs of cytochrome C immuno-stained sections from the left ventricle of the myocardium in the different experimental groups: ( a ) Group I (control group) showed minimal cytoplasmic immune expression of cytochrome C in the myocardium; ( b ) Group IIa (DOX/Trz group) showed marked cytoplasmic immuno-expression of cytochrome C in the myocardium; ( c ) Group IIb (recovery group) showed moderate cytoplasmic immuno-expression of cytochrome C in the myocardium; ( d ) Group III (prophylactic group) showed minimal cytoplasmic immuno-expression of cytochrome C in the myocardium; ( e ) Group IV (curative group) showed few cytoplasmic immuno-expression of cytochrome C in the myocardium; and ( f ) Histogram representing the mean area percentage of cytochrome C immuno-reaction in all experimental groups. **, significant compared to Group I at p ˂ 0.01; ##, significant compared to Group II at p ˂ 0.01; $, significant compared to Group III at p ˂ 0.05; n = 6.

Article Snippet: After blocking the endogenous activity of peroxidase using 10% hydrogen peroxide, the sections were blocked for non-specific reactions and incubated with primary rabbit polyclonal antibodies against Cytochrome c (SAB4502234; 1:50–1:100 dilutions; Sigma-Aldrich, St Louis, MO, USA), rabbit monoclonal antibodies against caspase-3 (ab32351; 1/25–1/100 dilutions; Abcam, Cambridge, UK), mouse monoclonal [C2C12] against NCX1 (ab2869; 5 µg/mL concentration; heat-mediated antigen retrieval performed with citrate buffer of pH 6 before commencing with IHC staining protocol; Abcam, Cambridge, UK), and rabbit polyclonal to SERCA2 ATPase (ab3625; 1 µg/mL concentration; heat-mediated antigen retrieval performed before commencing IHC staining protocol; Abcam, Cambridge, UK).

Techniques: Staining, Expressing

Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: HLA-A and HLA-DRB1 may play a unique role in ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis

doi: 10.1186/s12958-020-00661-5

Figure Lengend Snippet: Immunohistochemical findings in the teratoma tissues of the NMDAR-E group and the control group. a HLA-A (+) cells were more densely aggregated in the teratoma tissues in the NMDAR-E (+) patients in comparison with those in the controls. b HLA-DRB1 (+) cells were evident in the teratoma tissues in the NMDAR-E (+) patients but were scarcely detected in the controls. c The IHC score values of HLA-A and HLA-DRB1 were significantly higher in the teratoma tissues of NMDAR-E (+) patients compared with those in tissues of controls. There were eight teratoma patients without NMDAR-E in the control group (C-01 to 08) and 4 teratoma patients with NMDAR-E in the NMDAR-E group (S-01 to 04). Data are represented as the mean ± SD. * P < .05, ** P < .01. bar = 100 μm. (★: blood vessels, ▲: lymphatic vessels, ✚: germinal center, ↓: hair follicle, ←: sebaceous glands, red square: neuron, black square: glial cells)

Article Snippet: Rabbit polyclonal antibodies against HLA Class II DRB1 (HLA-DRB1) (1:2000, ab133578, Abcam, UK) and HLA Class I A (HLA-A) (1:400, ab52922, Abcam, UK) were used as the primary antibodies.

Techniques: Immunohistochemical staining

Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: HLA-A and HLA-DRB1 may play a unique role in ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis

doi: 10.1186/s12958-020-00661-5

Figure Lengend Snippet: Western blotting validation of differentially expressed proteins. a Verification of the expression of HLA-A and HLA-DRB1 in the control group and NMDAR-E group by western blotting analysis. The full-length blots are presented in Supplementary Fig. . b Quantitative assessment of protein expression using densitometric analysis. Four teratoma patients without NMDAR-E were in the control group (C-01 to 04), and 4 teratoma patients with NMDAR-E were in the NMDAR-E group (S-01 to 04). Data are represented as the mean ± SD. * P < .05

Article Snippet: Rabbit polyclonal antibodies against HLA Class II DRB1 (HLA-DRB1) (1:2000, ab133578, Abcam, UK) and HLA Class I A (HLA-A) (1:400, ab52922, Abcam, UK) were used as the primary antibodies.

Techniques: Western Blot, Expressing

Journal: Oncology Reports

Article Title: M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF

doi: 10.3892/or.2020.7628

Figure Lengend Snippet: In CAL27 cells, inhibition of EGFR by small molecule inhibitor results in reduced NHEJ repair capacity. (A) CAL27 and CAL27 with HB-EGF (50 ng/ml) were assessed by the western blot analysis with anti-EGFR and anti-p-EGFR antibodies. (B) EGFR and EGFR phosphorylation expression in CAL27 cells with or without HB-EGF after 4 Gy radiation. NC, CAL27 cells. (C) Representative images of the number of the p-DNA-PK foci per cell in 5 h after irradiation (4 Gy) in CAL27 cells with or without the EGFR inhibitor; magnification, ×200 (green, p-DNA-PK staining; blue, DAPI). (D) Representative images of the number of the RAD51 foci per cell in 5 h after irradiation (4 Gy) in CAL27 cells with or without the EGFR inhibitor; magnification ×200 (green, p-DNA-PK staining; blue, DAPI). *P<0.05. In CAL27 cells, inhibition of EGFR by small molecule inhibitor results in reduced NHEJ repair capacity. (E-a) Number of p-DNA-PK foci of NHEJ specific markers in CAL27 cells with or without EGFR inhibitors; (E-b) Number of RAD51 foci of HR specific markers in CAL27 cells with or without EGFR inhibitors. (F) IHC analyses of EGFR in cancer and normal tissues; magnification, ×400 (HPV + T, HPV-positive tumor tissues; HPV-T, HPV-negative tumor tissues; HPV + /HPV − N, head and neck normal tissues). (G) EGFR IHC score. HPV-positive cancer tissues (n=19), HPV-negative cases (n=33). (H) Expression of EGFR between HPV-positive (n=98) and HPV-negative (n=420) HNSCC in the TCGA database. Results are presented as the mean ± SD. *P<0.05. HPV, human papilloma virus; HNSCC, head and neck squamous cell carcinoma; EGFR, epidermal growth factor receptor; NHEJ, non-homologous end-joining; HB-EGF, heparin-binding epidermal growth factor; p-, phosphorylated; DNA-PK, DNA-dependent protein kinase; RAD51, RAD51 recombinase; IHC, immunohistochemistry; TCGA, The Cancer Genome Atlas.

Article Snippet: Samples were incubated with the γ H2A histone family member X (H2AX) mouse monoclonal antibody (product code ab26350; Abcam) at 1:500 dilution, primary rabbit polyclonal antibodies against RAD51 recombinase (RAD51; product code ab133534; Abcam) at 1:200, and phosphorylated (p)-DNA-dependent protein kinase (DNA-PK; phosphor S2056; product code ab124918; Abcam) at 1:200 and EGFR inhibitor gefitinib (ZD1839; cat. no. HY-50895; MedChemExpress) overnight at 4°C.

Techniques: Inhibition, Western Blot, Expressing, Irradiation, Staining, Non-Homologous End Joining, Binding Assay, Immunohistochemistry